Stockholm-based life science company HAGA.BIO (formerly known as VoxlBio) has raised a SEK 20.9 million (~$2.2–2.3M) seed round in June 2026 to accelerate commercialization of its spatial biology platform.
The round was backed by existing investors including Almi Invest, Life Science Invest, and SU Ventures, along with additional undisclosed life science investors.
What HAGA.BIO does
HAGA.BIO develops spatial biology technologies designed for validation and translational workflows, bridging the gap between biomarker discovery and clinical application.
Its platform focuses on enabling scalable, cost-efficient validation of spatial RNA biomarkers, addressing one of the key bottlenecks in modern biomedical research: moving discoveries from lab settings into clinical use.
Key technical focus areas include:
- spatial RNA biomarker validation
- in situ detection of single nucleotide variants (SNVs)
- high-throughput tissue analysis workflows
- translational research applications
Funding details
- Round: Seed
- Amount: SEK 20.9M (~$2.2–2.3M)
- Date: June 2026
- Sector: BioTech / Spatial Biology
- HQ: Stockholm, Sweden
- Previous name: VoxlBio
Technology and platform
The company is developing proprietary tools including:
- HAGA Pattern™ – multiplexed spatial gene expression assay
- HAGA Point™ – spatial assay for in situ SNV detection
These technologies are built on next-generation in situ hybridization methods aimed at improving sensitivity and scalability in tissue-based RNA analysis.
Market context
Spatial biology is one of the fastest-growing areas in life sciences, driven by demand for better understanding of how gene expression varies across tissue environments.
However, a major industry bottleneck remains clinical translation and large-scale validation, where cost, throughput, and reproducibility challenges persist.
HAGA.BIO positions itself directly in this gap, focusing not on discovery, but on validation at scale and clinical readiness.
Company link
Official website: HAGA.BIO
Bottom line
With strong backing from Nordic life science investors and a clear focus on translational spatial biology, HAGA.BIO is targeting a critical infrastructure gap in biotech: turning high-resolution biological discovery into clinically usable diagnostics and validated biomarkers.
